Is Beyond Air, Inc. (XAIR) Halal?
Shariah Screening — 5 Standards
Based on financial data from March 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 137.2% / 30% | 81.2% / 30% | 10.1% / 30% | 24.91% / 5% | ✗ NOT HALAL |
| DJIM | 137.2% / 33% | 81.2% / 33% | 10.1% / 33% | 24.91% / 5% | ✗ NOT HALAL |
| MSCI | 38.9% / 33% | 23.0% / 33% | 2.9% / 33% | 24.91% / 5% | ✗ NOT HALAL |
| S&P | 137.2% / 33% | 81.2% / 33% | 10.1% / 33% | 24.91% / 5% | ✗ NOT HALAL |
| FTSE | 38.9% / 33% | 23.0% / 33% | 2.9% / 50% | 24.91% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 1.8% | |
| Operating Margin | -300.6% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -240.2% | |
| Return on Assets (ROA) | -51.2% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$38M |
| Free Cash Flow | -$44M |
| Total Debt | $12M |
| Debt-to-Equity | 284.7 |
| Current Ratio | 5.1 |
| Total Assets | $30M |
Price & Trading
| Last Close | $0.69 |
| 50-Day MA | $1.06 |
| 200-Day MA | $1.98 |
| Avg Volume | 7.8M |
| Beta | 0.4 |
|
52-Week Range
$0.67
| |
About Beyond Air, Inc. (XAIR)
Beyond Air, Inc., a commercial-stage medical device and biopharmaceutical company, develops the Lungfit platform, a nitric oxide (NO) generator and delivery system platform. It operates through three segments: Beyond Air, Beyond Cancer, and NeuroNos. The company offers Lungfit PH for the treatment of persistent pulmonary hypertension of the newborn. It is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired pneumonia, including COVID-19 and bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria (NTM) at home. In addition, the company develops ultra-high concentration (UNO) that is in Phase 1 clinical trial to treat multiple solid and cutaneous tumors; and selective neuronal nitric oxide synthase (nNOS) inhibitor for the treatment of neurological conditions and autism spectrum disorder. It has a collaboration with the Yissum Research Development Company of the Hebrew University of Jerusalem, LTD to acquire the commercial rights for neuronal nitric oxide synthase inhibitors to treat autism spectrum disorder and other neurological conditions. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. was founded in 2011 and is headquartered in Garden City, New York.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Beyond Air, Inc. (XAIR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Beyond Air, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Beyond Air, Inc.'s debt ratio?
Beyond Air, Inc.'s debt ratio is 137.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 38.9%.
What are Beyond Air, Inc.'s key financial metrics?
Beyond Air, Inc. has a market capitalization of $8M, and revenue of $4M. Return on equity stands at -240.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.